TIME COURSE OF TREATMENT-RELATED ADVERSE EVENTS (TRAES) DURING DOSTARLIMAB THERAPY IN THE GARNET TRIAL

被引：0

作者：

Pothuri, Bhavana ^{[1
,2
]}

Berton, Dominique ^{[3
,4
]}

Moreno, Victor ^{[5
]}

Oaknin, Ana ^{[6
]}

Perez, Jose Manuel Trigo ^{[7
]}

Curigliano, Giuseppe ^{[8
,9
]}

Ellard, Susan ^{[10
]}

Pikiel, Joanna ^{[11
]}

Banerjee, Susana ^{[12
,13
]}

Barretina-Ginesta, Maria-Pilar ^{[14
]}

Miller, Rowan ^{[15
]}

Tinker, Anna ^{[16
]}

Jewell, Andrea ^{[17
]}

Plummer, Ruth ^{[18
]}

Joly, Florence ^{[19
]}

Veneris, Jennifer ^{[20
]}

Duan, Tao ^{[20
]}

Andre, Thierry ^{[21
,22
]}

机构：

[1] NYU Langone Hlth, Perlmutter Canc Ctr, Gynecol Oncol Grp GOG, New York, NY USA

[2] NYU Langone Hlth, Perlmutter Canc Ctr, Dept Obstet Gynecol, New York, NY USA

[3] Ctr Rene Gauducheau, GINECO, St Herblain, France

[4] Ctr Rene Gauducheau, Inst Cancerol Ouest, St Herblain, France

[5] Fdn Jimenez Diaz Hosp, START Madrid FJD, Madrid, Spain

[6] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol VHIO, Barcelona, Spain

[7] Hosp Virgen Victoria IBIMA, Med Oncol Dept, Malaga, Spain

[8] IRCCS, European Inst Oncol, IEO, Div Early Drug Dev Innovat Therapies, Milan, Italy

[9] Univ Milan, Milan, Italy

[10] BC Canc Kelowna, Kelowna, BC, Canada

[11] Reg Ctr Oncol, Gdansk, Poland

[12] Royal Marsden NHS Fdn Trust, London, England

[13] Inst Canc Res, London, England

[14] Hosp Univ Dr J Trueta, Inst Catala Oncol, Girona, Spain

[15] UCL, St Bartholomews Hosp London, London, England

[16] BC Canc, Vancouver, BC, Canada

[17] Univ Kansas, Med Ctr, Kansas City, KS 66103 USA

[18] Newcastle Univ, Med Sch, Northern Inst Canc Res, London, England

[19] Ctr Francois Baclesse, Med Oncol Dept, Caen, France

[20] GlaxoSmithKline, London, England

[21] Sorbonne Univ, Paris, France

[22] St Antoine Hosp, Paris, France

来源：

JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2021年 / 9卷

关键词：

D O I：

10.1136/jitc-2021-SITC2021.370

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

370

引用

页码：A398 / A398

页数：1

共 50 条

[21] Time course profile of adverse events of interest and serious adverse events with darolutamide in the ARAMIS trial
Gratzke, C. J.
Fizazi, K.
Shore, N. D.
Smith, M. R.
Feyerabend, S.
Grabbert, M.
Carles, J.
Lebret, T.
Vjaters, E.
Werbrouck, P.
Miskic, M.
Ortiz, J.
Schmall, A.
Le Berre, M. A.
Verholen, F.
ANNALS OF ONCOLOGY, 2021, 32 : S664 - S664
[22] Time Course Profile of Adverse Events of Interest and Serious Adverse Events With Darolutamide in the ARAMIS Trial
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (11) : 13 - 14
[23] Randomized Prospective Trial Exploring the Impact of Structured Journaling in Patients With Sarcoma on the Management of Treatment-Related Adverse Events
Speece, N. J.
Xu, Menglin
Tinoco, Gabriel
Liebner, David A.
Chen, James L.
JCO ONCOLOGY PRACTICE, 2022, 18 (02) : 151 - +
[24] Sinonasal mucosal melanoma: An analysis of treatment-related adverse events and associated factors
Johnson, Brian J. J.
Guo, Ruifeng
Moore, Eric J. J.
Price, Daniel L. L.
Van Abel, Kathryn M. M.
Van Gompel, Jamie J. J.
Link, Michael J. J.
Peris-Celda, Maria
Stokken, Janalee K. K.
Pinheiro-Neto, Carlos
Kottschade, Lisa
Markovic, Svetomir
Block, Matthew
McWilliams, Robert
Montane, Heather
Dimou, Anastasios
Gergelis, Kimberly
Gamez, Mauricio E. E.
Choby, Garret
INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY, 2023, 13 (06) : 1037 - 1041
[25] Treatment-related adverse events associated with antibody drug conjugate in breast cancer
Collineau, Berenice
Goncalves, Anthony
Bertucci, Francois
de Nonneville, Alexandre
BULLETIN DU CANCER, 2024, 111 (7-8) : 765 - 781
[26] Treatment-related adverse events as surrogate to response rate to immune checkpoint blockade
Shen, Yanyun
Chen, Yunfeng
Wang, Duoqin
Zhu, Zhidong
MEDICINE, 2020, 99 (37)
[27] THE IMPACT OF HIV TREATMENT-RELATED ADVERSE EVENTS ON ADHERENCE TO ANTIRETROVIRAL THERAPY: A SYSTEMATIC REVIEW AND META-ANALYSIS
Maiese, E. M.
Al-Dakkak, I
McCann, E.
Patel, S.
Gadkari, A.
Prajapati, G.
VALUE IN HEALTH, 2012, 15 (04) : A245 - A245
[28] Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice
O'Brien, Susan M.
Brown, Jennifer R.
Byrd, John C.
Furman, Richard R.
Ghia, Paolo
Sharman, Jeff P.
Wierda, William G.
FRONTIERS IN ONCOLOGY, 2021, 11
[29] Prevalence of treatment-related adverse events (TRAEs) with antibody-drug conjugates in metastatic breast cancer patients: A systematic review and meta-analysis (vol 204, 104527, 2024)
Belloni, Silvia
Tiberio, Paola
De Sanctis, Rita
Magon, Arianna
Santoro, Armando
Zambelli, Alberto
Caruso, Rosario
Arrigoni, Cristina
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2024, 204
[30] A sunitinib exposure-effect based meta-analysis of treatment-related adverse events (TRAEs) in patients with metastatic renal cell carcinoma (RCC) and gastrointestinal stromal tumor (GIST).
Houk, B. E.
Bello, C.
Cohen, D.
Kuwabara-Wagg, J.
Poland, B.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 : S53 - S53

← 1 2 3 4 5 →